ACAD FY 2025 Earnings Report — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADIA Pharmaceuticals Inc.ACAD

FY 2025 Earnings

Reported February 25, 2026

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2025	Prior Q	FY 2024	QoQ Change	YoY Change
Revenue	$1.1B	—	$958M	—	11.9%
Op. Income	$105M	—	$231M	—	-54.6%
Gross Margin	91.7%	—	91.5%	—	0.2pp
Net Margin	36.5%	—	23.6%	—	12.8pp
EPS (Diluted)	$2.29	—	$1.36	—	68.4%
Free Cash Flow	$105M	—	$157M	—	-33.1%

Revenue Flow

Item	Amount
REVENUE	$1.1B
Cost of Revenue	$89M
GROSS PROFIT	$983M
R&D Expenses	$329M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$549M
Other Expenses	$0
Operating Expenses	$878M
Cost & Expenses	$967M
OPERATING INCOME	$105M
Interest Income	$32M
Interest Expense	$0
Other Income/Expenses	$34M
INCOME BEFORE TAX	$139M
Income Tax Expense	-$252M
Net Income from Continuing Ops	$391M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$391M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$391M
D&A	$0
EBIT	$139M
EBITDA	$139M
EPS	$2
EPS Diluted	$2

Income Statement

Item	Amount
REVENUE	$1.1B
Cost of Revenue	$89M
GROSS PROFIT	$983M
R&D Expenses	$329M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$549M
Other Expenses	$0
Operating Expenses	$878M
Cost & Expenses	$967M
OPERATING INCOME	$105M
Interest Income	$32M
Interest Expense	$0
Other Income/Expenses	$34M
INCOME BEFORE TAX	$139M
Income Tax Expense	-$252M
Net Income from Continuing Ops	$391M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$391M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$391M
D&A	$0
EBIT	$139M
EBITDA	$139M
EPS	$2
EPS Diluted	$2

Cash Flow Statement

Item	Amount
Net Income	$391M
Depreciation & Amortization	$12M
Stock-Based Compensation	$0
Deferred Income Tax	-$250M
Other Non-Cash Items	$47M
Change in Working Capital	-$90M
OPERATING CASH FLOW	$110M
Capital Expenditure	-$5M
Acquisitions (Net)	$0
Purchases of Investments	-$693M
Sales/Maturities of Investments	$494M
Other Investing Activities	$0
NET CASH FROM INVESTING	-$303M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$0
NET CASH FROM FINANCING	$50M
FREE CASH FLOW	$105M
Net Change in Cash	-$142M

Balance Sheet

Item	Amount
Cash & Equivalents	$178M
Short-Term Investments	$642M
Net Receivables	$148M
Inventory	$35M
Other Current Assets	$0
TOTAL CURRENT ASSETS	$1.1B
PP&E (Net)	$55M
Goodwill	$0
Intangible Assets	$109M
Long-Term Investments	$8M
Tax Assets	$250M
Other Non-Current Assets	$81M
TOTAL NON-CURRENT ASSETS	$502M
TOTAL ASSETS	$1.6B
Account Payables	$11M
Short-Term Debt	$12M
Deferred Revenue	$0
Other Current Liabilities	$255M
TOTAL CURRENT LIABILITIES	$277M
Long-Term Debt	$0
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$19M
TOTAL NON-CURRENT LIABILITIES	$60M
TOTAL LIABILITIES	$337M
Common Stock	$16.0K
Additional Paid-In Capital	$3.0B
Retained Earnings	-$1.8B
Treasury Stock	$0
Accum. Other Comp. Income	$1M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$1.2B
Minority Interest	$0
TOTAL EQUITY	$1.2B
TOTAL LIABILITIES & EQUITY	$1.6B
Total Debt	$52M
Net Debt	-$126M